2-[(3S,6S,9Z,12S,15S,18R,24R,27S)-24-(2-aminoethyl)-15-(3-aminopropyl)-3-[(1S)-2-chloro-1-hydroxyethyl]-27-(3,4-dihydroxyhexadecanoylamino)-9-ethylidene-12-[(1S)-1-hydroxyethyl]-18-(2-hydroxyethyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-6-yl]-2-hydroxyacetic acid
| Internal ID | cf4d2b1a-1108-4618-b811-5602ffbcd102 |
| Taxonomy | Organic acids and derivatives > Peptidomimetics > Depsipeptides > Cyclic depsipeptides |
| IUPAC Name | 2-[(3S,6S,9Z,12S,15S,18R,24R,27S)-24-(2-aminoethyl)-15-(3-aminopropyl)-3-[(1S)-2-chloro-1-hydroxyethyl]-27-(3,4-dihydroxyhexadecanoylamino)-9-ethylidene-12-[(1S)-1-hydroxyethyl]-18-(2-hydroxyethyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-6-yl]-2-hydroxyacetic acid |
| SMILES (Canonical) | |
| SMILES (Isomeric) | |
| InChI | InChI=1S/C50H86ClN11O19/c1-4-6-7-8-9-10-11-12-13-14-17-33(65)34(66)23-36(68)56-32-26-81-50(80)39(35(67)24-51)61-48(77)40(41(70)49(78)79)62-43(72)28(5-2)57-47(76)38(27(3)64)60-45(74)29(16-15-20-52)58-44(73)31(19-22-63)55-37(69)25-54-42(71)30(18-21-53)59-46(32)75/h5,27,29-35,38-41,63-67,70H,4,6-26,52-53H2,1-3H3,(H,54,71)(H,55,69)(H,56,68)(H,57,76)(H,58,73)(H,59,75)(H,60,74)(H,61,77)(H,62,72)(H,78,79)/b28-5-/t27-,29-,30+,31+,32-,33?,34?,35+,38-,39-,40-,41?/m0/s1 |
| InChI Key | GWHDYRUDHBDIPD-HRDZNJMGSA-N |
| Popularity | 3 references in papers |
| Molecular Formula | C50H86ClN11O19 |
| Molecular Weight | 1180.70 g/mol |
| Exact Mass | 1179.5789972 g/mol |
| Topological Polar Surface Area (TPSA) | 499.00 Ų |
| XlogP | -2.60 |
| Atomic LogP (AlogP) | -5.61 |
| H-Bond Acceptor | 20 |
| H-Bond Donor | 18 |
| Rotatable Bonds | 27 |
| There are no found synonyms. |
![2D Structure of 2-[(3S,6S,9Z,12S,15S,18R,24R,27S)-24-(2-aminoethyl)-15-(3-aminopropyl)-3-[(1S)-2-chloro-1-hydroxyethyl]-27-(3,4-dihydroxyhexadecanoylamino)-9-ethylidene-12-[(1S)-1-hydroxyethyl]-18-(2-hydroxyethyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-6-yl]-2-hydroxyacetic acid](https://plantaedb.com/storage/docs/compounds/2023/11/f9d9c430-85bb-11ee-8e60-9bb30c2b7cef.jpg "2D Structure of 2-[(3S,6S,9Z,12S,15S,18R,24R,27S)-24-(2-aminoethyl)-15-(3-aminopropyl)-3-[(1S)-2-chloro-1-hydroxyethyl]-27-(3,4-dihydroxyhexadecanoylamino)-9-ethylidene-12-[(1S)-1-hydroxyethyl]-18-(2-hydroxyethyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-6-yl]-2-hydroxyacetic acid")
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | + | 0.5774 | 57.74% |
| Caco-2 | - | 0.8593 | 85.93% |
| Blood Brain Barrier | - | 0.8250 | 82.50% |
| Human oral bioavailability | - | 0.6714 | 67.14% |
| Subcellular localzation | Mitochondria | 0.4866 | 48.66% |
| OATP2B1 inhibitior | - | 1.0000 | 100.00% |
| OATP1B1 inhibitior | + | 0.8161 | 81.61% |
| OATP1B3 inhibitior | + | 0.9185 | 91.85% |
| MATE1 inhibitior | - | 0.9400 | 94.00% |
| OCT2 inhibitior | - | 0.9250 | 92.50% |
| BSEP inhibitior | + | 0.9044 | 90.44% |
| P-glycoprotein inhibitior | + | 0.7416 | 74.16% |
| P-glycoprotein substrate | + | 0.8645 | 86.45% |
| CYP3A4 substrate | + | 0.7295 | 72.95% |
| CYP2C9 substrate | - | 0.8012 | 80.12% |
| CYP2D6 substrate | - | 0.8536 | 85.36% |
| CYP3A4 inhibition | - | 0.7329 | 73.29% |
| CYP2C9 inhibition | - | 0.8833 | 88.33% |
| CYP2C19 inhibition | - | 0.8609 | 86.09% |
| CYP2D6 inhibition | - | 0.9080 | 90.80% |
| CYP1A2 inhibition | - | 0.8636 | 86.36% |
| CYP2C8 inhibition | + | 0.7383 | 73.83% |
| CYP inhibitory promiscuity | - | 0.9805 | 98.05% |
| UGT catelyzed | - | 0.7000 | 70.00% |
| Carcinogenicity (binary) | - | 0.7500 | 75.00% |
| Carcinogenicity (trinary) | Non-required | 0.5061 | 50.61% |
| Eye corrosion | - | 0.9825 | 98.25% |
| Eye irritation | - | 0.8968 | 89.68% |
| Skin irritation | - | 0.7526 | 75.26% |
| Skin corrosion | - | 0.9216 | 92.16% |
| Ames mutagenesis | - | 0.6500 | 65.00% |
| Human Ether-a-go-go-Related Gene inhibition | + | 0.7036 | 70.36% |
| Micronuclear | + | 0.7800 | 78.00% |
| Hepatotoxicity | - | 0.5853 | 58.53% |
| skin sensitisation | - | 0.8413 | 84.13% |
| Respiratory toxicity | + | 0.7000 | 70.00% |
| Reproductive toxicity | + | 0.8222 | 82.22% |
| Mitochondrial toxicity | + | 0.8250 | 82.50% |
| Nephrotoxicity | + | 0.8942 | 89.42% |
| Acute Oral Toxicity (c) | III | 0.6593 | 65.93% |
| Estrogen receptor binding | + | 0.7272 | 72.72% |
| Androgen receptor binding | + | 0.7088 | 70.88% |
| Thyroid receptor binding | + | 0.5279 | 52.79% |
| Glucocorticoid receptor binding | + | 0.6019 | 60.19% |
| Aromatase binding | + | 0.6586 | 65.86% |
| PPAR gamma | + | 0.7133 | 71.33% |
| Honey bee toxicity | - | 0.7355 | 73.55% |
| Biodegradation | - | 0.7750 | 77.50% |
| Crustacea aquatic toxicity | - | 0.5192 | 51.92% |
| Fish aquatic toxicity | + | 0.6775 | 67.75% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL4040 | P28482 | MAP kinase ERK2 | 99.99% | 83.82% |
| CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 99.65% | 94.45% |
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 99.32% | 91.11% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 98.12% | 96.09% |
| CHEMBL230 | P35354 | Cyclooxygenase-2 | 98.05% | 89.63% |
| CHEMBL2581 | P07339 | Cathepsin D | 97.47% | 98.95% |
| CHEMBL4296 | Q15858 | Sodium channel protein type IX alpha subunit | 96.68% | 96.11% |
| CHEMBL4187 | Q99250 | Sodium channel protein type II alpha subunit | 96.15% | 95.50% |
| CHEMBL3130 | O00329 | PI3-kinase p110-delta subunit | 96.14% | 96.47% |
| CHEMBL1907605 | P24864 | Cyclin-dependent kinase 2/cyclin E1 | 95.83% | 92.88% |
| CHEMBL3892 | Q99500 | Sphingosine 1-phosphate receptor Edg-3 | 95.72% | 97.29% |
| CHEMBL2208 | P49137 | MAP kinase-activated protein kinase 2 | 95.16% | 95.20% |
| CHEMBL3060 | Q9Y345 | Glycine transporter 2 | 94.86% | 99.17% |
| CHEMBL2955 | O95136 | Sphingosine 1-phosphate receptor Edg-5 | 94.60% | 92.86% |
| CHEMBL1293267 | Q9HC97 | G-protein coupled receptor 35 | 94.16% | 89.34% |
| CHEMBL226 | P30542 | Adenosine A1 receptor | 94.02% | 95.93% |
| CHEMBL3392948 | Q9NP59 | Solute carrier family 40 member 1 | 93.98% | 95.00% |
| CHEMBL299 | P17252 | Protein kinase C alpha | 93.54% | 98.03% |
| CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 93.53% | 96.90% |
| CHEMBL2107 | P61073 | C-X-C chemokine receptor type 4 | 92.72% | 93.10% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 92.71% | 97.09% |
| CHEMBL3038469 | P24941 | CDK2/Cyclin A | 92.30% | 91.38% |
| CHEMBL3145 | P42338 | PI3-kinase p110-beta subunit | 90.91% | 98.75% |
| CHEMBL4481 | P35228 | Nitric oxide synthase, inducible | 90.83% | 94.80% |
| CHEMBL4588 | P22894 | Matrix metalloproteinase 8 | 90.73% | 94.66% |
| CHEMBL236 | P41143 | Delta opioid receptor | 90.60% | 99.35% |
| CHEMBL3267 | P48736 | PI3-kinase p110-gamma subunit | 90.15% | 95.71% |
| CHEMBL221 | P23219 | Cyclooxygenase-1 | 89.81% | 90.17% |
| CHEMBL5103 | Q969S8 | Histone deacetylase 10 | 89.81% | 90.08% |
| CHEMBL4685 | P14902 | Indoleamine 2,3-dioxygenase | 89.65% | 96.38% |
| CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 89.20% | 100.00% |
| CHEMBL4581 | P52732 | Kinesin-like protein 1 | 88.97% | 93.18% |
| CHEMBL3837 | P07711 | Cathepsin L | 88.81% | 96.61% |
| CHEMBL3807 | P17706 | T-cell protein-tyrosine phosphatase | 88.27% | 93.00% |
| CHEMBL218 | P21554 | Cannabinoid CB1 receptor | 88.23% | 96.61% |
| CHEMBL2885 | P07451 | Carbonic anhydrase III | 88.18% | 87.45% |
| CHEMBL5845 | P23415 | Glycine receptor subunit alpha-1 | 87.96% | 90.71% |
| CHEMBL4227 | P25090 | Lipoxin A4 receptor | 86.90% | 100.00% |
| CHEMBL3401 | O75469 | Pregnane X receptor | 85.34% | 94.73% |
| CHEMBL2072 | P35499 | Sodium channel protein type IV alpha subunit | 85.23% | 92.32% |
| CHEMBL5469 | Q14289 | Protein tyrosine kinase 2 beta | 85.10% | 91.03% |
| CHEMBL1907589 | P17787 | Neuronal acetylcholine receptor; alpha4/beta2 | 85.01% | 94.55% |
| CHEMBL3384 | Q16512 | Protein kinase N1 | 84.51% | 80.71% |
| CHEMBL1907602 | P06493 | Cyclin-dependent kinase 1/cyclin B1 | 84.25% | 91.24% |
| CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 83.77% | 95.56% |
| CHEMBL1806 | P11388 | DNA topoisomerase II alpha | 83.03% | 89.00% |
| CHEMBL4478 | Q00975 | Voltage-gated N-type calcium channel alpha-1B subunit | 83.03% | 97.14% |
| CHEMBL1801 | P00747 | Plasminogen | 82.76% | 92.44% |
| CHEMBL2514 | O95665 | Neurotensin receptor 2 | 82.09% | 100.00% |
| CHEMBL255 | P29275 | Adenosine A2b receptor | 81.29% | 98.59% |
| CHEMBL1075317 | P61964 | WD repeat-containing protein 5 | 81.14% | 96.33% |
| CHEMBL2693 | Q9UIQ6 | Cystinyl aminopeptidase | 80.93% | 97.64% |
| CHEMBL3310 | Q96DB2 | Histone deacetylase 11 | 80.78% | 88.56% |
| CHEMBL2111367 | P27986 | PI3-kinase p110-alpha/p85-alpha | 80.53% | 94.33% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| There are no matching plants. |
| PubChem | 101623470 |
| LOTUS | LTS0269125 |
| wikiData | Q105022369 |